Skip to main content
. 2023 Apr 2;11(4):1071. doi: 10.3390/biomedicines11041071

Table 1.

Novel immune checkpoint inhibitors: ongoing clinical trials in RCC.

Target Drug Clinical Trials
LAG-3 IMP231
Relatlimab
NCT00351949
NCT05148546
TIM-3 Sabatolimab
INCAGN02390
NCT02608268
NCT03652077
VISTA CA-170 NCT02812875
IDO1 Navoximod NCT02471846